Individual Member

TERI POLLASTRO

Teri Pollastro was diagnosed with HER2+ metastatic breast cancer in 2003 when her children were 3 and 7. Teri was treated with chemotherapy, Herceptin, shaped beam radiation treatment (SBRT), and participated in a phase 1 vaccine clinical trial. She remains on Herceptin today.

 

Teri is involved in a variety of advocacy projects both locally and nationally.  She is an advocate on many DoD grants and is currently one of four advocates in the Translational Breast Cancer Consortium. She also works closely with the University of WA Cancer Vaccine Institute (CVI) and serves on their patient advisory board. She is a member of the advisory group for Fred Hutch Met X program which serves all metastatic cancers. She meets with newly diagnosed mbc patients as needed.

 

Teri previously served as the co-chair for the NW Metastatic Breast Cancer Conference in Seattle, WA, a Co-Chair for the MBCA Research Task Force, a member at large for the MBCA executive group, an advocate on the ASCO Research Task Force Committee, and a patient advocate representing the University of WA for the TBCRC.

 

In her spare time, Teri enjoys spending time with her family, reading, traveling, hiking, and playing tennis (not very well).

WHAT I'M WORKING ON

Education & AwarenessResearch

Thought Leader Interviews and Survey

The MBCA has begun work to update this section of Chapter 2 of the Landscape Analysis, report the current landscape of MBC research, and gather knowledge that will inform the 5-year MBCA strategic plan beginning in 2022.

Link to program
ResearchFunding

MBC Research Funding Update

As in the original analysis, the research grant analysis in 2021 and subsequent years will help to identify gaps in research and opportunities for future Alliance resource allocation and provide insight into new drug targets or potential targets poised for development and clinical translation that may further inform Alliance priorities or activities.

Link to program